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Fifteen antiretroviral Zn-finger active compounds with diverse chemical structures, 
including azoic compounds, hydrazide derivatives, disulfide-based reagents and others,  
were screened in vitro against Junin virus (JUNV), the etiological agent of Argentine 
hemorrhagic fever, by a virus yield inhibition assay in Vero cells. Cytotoxicity was 
evaluated simultaneously by the MTT method. From the total of compounds, three were 
totally inactive as antivirals, nine presented moderate anti JUNV-activity and three were 
truly active with EC50 (effective concentration 50%) values in the range 6.5-9.3 µM and 
selectivity indices greater than 10. The most active inhibitors, named NSC20625, 3-7 
and 2-71, demonstrated a broad range of action against arenaviruses, including several 
attenuated and pathogenic strains of JUNV as well as the antigenically related Tacaribe 
virus (TACV) and Pichinde virus (PICV). The direct treatment of JUNV and TACV 
virions with the compounds has shown two types of behavior: the aromatic disulfide 
NSC20625 was a very potent virucidal agent, whereas the other two compounds 
exhibited  moderate or negligible virus inactivating properties. 
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Arenaviridae is a family of enveloped viruses containing two genome single-stranded 
RNA segments, a large (L) and a small (S) fragment, both with ambisense coding 
arrangement. Only five proteins are expressed from the two genome fragments : the S 
RNA encodes the major structural proteins, the nucleocapsid protein (NP) and the two 
envelope glycoproteins (the external GP1 and the transmembrane GP2), whereas the L 
RNA encodes the RNA polymerase protein L and a 11-kda protein called Z or p11 with 
unknown function. The Z protein was the last to be described when the sequences of the 
L segments of lymphocytic choriomeningitis virus (LCMV) (Salvato & Shimomaye, 
1989), Tacaribe virus (TACV) (Iapalucci et al., 1989), and Lassa virus (Djavani et al., 
1997) were completed. The Z protein sequence in members of Arenaviridae maintains a 
Cys3HisCys4 RING-finger motif, a type of Zn-binding polypeptide sequence that 
coordinates two zinc ions (Saurin et al., 1996). It has been shown that the LCMV Z 
protein effectively binds Zn in vitro (Salvato & Shimomaye, 1989). 
Several arenaviruses are human pathogens causing severe hemorrhagic fevers. In 
particular, Junin virus (JUNV) is the agent of Argentine hemorrhagic fever (AHF), an 
endemo-epidemic disease affecting the population of the most fertile zone of Argentina 
(Weissenbacher et al., 1987). Although several compounds were found to be selective 
inhibitors of the in vitro replication of JUNV (Andrei & De Clercq, 1990; Candurra et 
al., 1996, 1999; Candurra & Damonte, 1999; Cordo et al., 1999), no reliable drug 
therapy is presently available for the treatment of AHF. Ribavirin is the only compound 
that has shown partial efficacy against JUNV infections but with a high level of 
undesirable secondary reactions (McKee et al., 1988; Enria & Maiztegui, 1994). Thus, 
the treatment of choice for AHF consists of the early administration of standardized 
doses of convalescent plasma, but this therapy is not efficient when it is initiated after 8 
days of illness and a late neurological syndrome is observed in 10% of the treated 
patients (Enria & Maiztegui, 1994). 
Zn-binding proteins with cysteine-rich Zn-finger motifs seem to represent a potential 
novel strategy for antiviral chemotherapy. Recent studies have identified a series of 
chemotypes that selectively target the retroviral Zn-finger motifs of the human 
immunodeficiency virus type 1 (HIV-1) nucleocapsid protein p7 (NCp7) causing Zn 
ejection from the protein, loss of its native structure and inhibition of virus replication 
(Rice et al., 1996; Tummino et al., 1997; Witvrouw et al., 1997). Since the Zn-binding 
domain in the 11 kda-Z protein of several arenaviruses is highly conserved turning this 
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protein an attractive target for antiviral action, in the present study we evaluated 
selected retroviral Zn-finger agents for their capacity to act as arenavirus inhibitors. 
Fifteen compounds with known activity toward HIV-1 NCp7 Zn-fingers and 
representative of diverse chemical structures were provided by Dr. William Rice, 
National Cancer Institute-Frederick Cancer Research and Development Center, SAIC 
Frederick, USA. Stock solutions at a concentration of 100 mM were prepared in 
dimethylsulfoxide. Ribavirin (Sigma-Aldrich, USA) was assayed as a reference 
substance. 
Antiviral activity was evaluated by a virus yield inhibition assay in Vero cell 
monolayers grown in 24-well microplates, and infected with JUNV, strain IV4454, in 
the presence of different concentrations of the compounds. After 48 h of infection, 
supernatant cultures were harvested and extracellular virus yields were determined by 
plaque formation. The effective concentration 50% (EC50) and the effective 
concentration 90% (EC90) were calculated as the concentrations required to reduce virus 
yield by 50% and 90%, respectively, in the compound-treated cultures compared with 
the untreated ones. Cytotoxicity was measured with 3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, USA) method in Vero cells grown 
in 96 well-plates, using conditions equivalent to those used in antiviral assays (48 h of 
incubation at 37°C), and results were expressed as the cytotoxic concentration 50% 
(CC50), compound concentration required to reduce the MTT signal by 50% compared 
to controls. 
The compounds tested were grouped in two categories according to their chemical 
structure, as shown in Tables 1 and 2. The first category of compounds consisted of 
eight diverse disulfide-based compounds. As shown in Table 1, all these compounds 
were moderate or highly active against JUNV, with EC50 values ranging from 4.6 to 100 
µM. However, the thiuram disulfide 5-7 was too toxic to be considered valuable as 
antiviral. Among the aromatic disulfides, two compounds (NSC4493 and NSC20625) 
were both selective inhibitors of JUNV with selectivity indices about 10, but NSC20625 
exhibited a strong efficacy because its EC50 was 4-fold lower than the corresponding to 
NSC4493. Finally, the two cis and trans isomers of 1,2-dithiane-4,5-diol, 1,1-dioxide 
(namely NSC624151 and NSC624152, respectively) demonstrated to be active against 
JUNV, although the cis-diol 624151 exerted a slightly superior effectivity with an EC50 
of 17.0 µM and CC50 > 400 µM. The most active inhibitors showed similar or higher 
efficacy in vitro than ribavirin (Table 1). 
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From the total of seven azoic and hydrazide derivatives tested, three were totally 
inactive, two demonstrated moderate anti-JUNV activity, whereas two compounds, 3-7, 
2-(2-nitroso-1-naphthylazo)benzoic acid, and 2-71, 2-(carbamoylthio)-acetic acid 2-
phenyl hydrazide, were truly active toward JUNV with EC50 values of 6.5 and 8.9 µM, 
respectively (Table 2). In addition, the CC50 of these two compounds greatly exceeded 
the effective antiviral doses, thus resulting in selectivity indices of 30.0 and 58.0 for 2-
71 and 3-7, respectively. 
The anti-arenavirus activity of both chemical classes of compounds was comparable to 
their antiretroviral effect against HIV previously reported (Rice et al., 1996; 1997a; 
1997b). 
The antiviral potency of the active compounds was also evaluated by a plaque reduction 
assay against JUNV in Vero cells. For example, the concentrations required to reduce 
plaque number by 50% for NSC20625, 2-71 and the reference compound ribavirin were 
5.7, 22.0  and 17.9 µM, respectively, values not much different in comparison to the 
EC50 obtained by virus yield inhibition assay (Tables 1 and 2). 
Three compounds, NSC20625, 3-7 and 2-71, representatives of different chemical 
structures and with EC50 values lower than 10 µM and SI greater than 10, were further 
examined for their inhibitory action on arenaviruses. As shown in Table 3, these 
compounds effectively inhibited the replication of several strains of JUNV, including 
attenuated isolates such as the above mentioned IV4454 and the XJCl3 and Cl67 strains 
as well as the highly pathogenic XJ strain. When other species of arenaviruses were 
tested, the values of EC50 for TACV, an arenavirus closely related to JUNV as shown 
by antigenic cross-reactivity and in vivo protection studies (Martinez Peralta et al., 
1993), and for Pichinde virus (PICV) were similar to those obtained for JUNV (Table 
3). In most cases, the disulfide NSC20625 was the most active compound. 
As a first approach to characterize the action of these three compounds on arenaviruses, 
an assay of virucidal activity was performed. To this end, a virus suspension containing 
1x10
6 
PFU of JUNV was exposed for 1.5 h at 37°C to various concentrations of 
compounds, and then samples were chilled and diluted to determine residual infectivity 
by plaque formation. The sample dilution effectively reduced the drug concentration to 
be incubated with the cells at least 100-fold and was below the effective antiviral 
concentration EC50. The comparison between the antiviral action in infected cells and 
the inactivating effect on virus particles against two arenaviruses, JUNV and TACV, 
shown in Figure 1, has evidenced different types of behavior for these three agents. The 
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aromatic disulfide NSC20625 was the most potent virucidal agent, reducing virus titers 
more than 3 log at concentrations below 5 µM. From the data of Figure 1, the 
inactivating concentration 50% (IC50) of NSC20625 was calculated to be 0.7 and 1.3 
µM against JUNV and TACV, respectively, whereas the corresponding EC50 values in 
virus yield inhibition assays were 9.3 and 3.6 µM, respectively (Table 3). The virucidal 
potency of NSC20625 was more clearly shown when the inactivating concentration 
90% (IC90) was compared to the virus yield effective concentration EC90: for JUNV the 
IC90 and the EC90 were 1.6 and 50.0 µM, respectively, whereas for TACV the IC90 was 
3.1 µM and the EC90 was 37.6 µM. By contrast, the compound 3-7 only inactivated 
TACV virion infectivity by 50 % at a concentration as high as 40 µM whereas its 
virucidal activity against JUNV was negligible. The compound 2-71 demonstrated an 
intermediate behavior with the same pattern of curves for antiviral and virucidal 
activities against both viruses (Figure 1), and the extrapolated values of IC50  (31.3 and 
21.1 µM for JUNV and TACV, respectively) were similar to the corresponding EC50 
shown in Table 3. 
The variable ability to inactivate JUNV and TACV virions demonstrated by the 
compounds shown in Figure 1, independently of their virus yield inhibitory effect, 
prompted us to evaluate the virucidal activity of all the series of Zn-finger active drugs. 
Results obtained confirmed the lack of a direct correlation between antiviral effect in 
infected cells and the virus inactivating action of these compounds. The two dithianes 
NSC624151 and 624152, the aldrithiol-2 4-16 and even the azodicarbonamide (ADA) 
A9660, inactive in virus yield inhibition assay (Table 2), exhibited a very important 
virucidal activity as NSC20625, with IC50 and IC90 values 5-15 fold lower than the 
corresponding EC50 and EC90 doses, whereas the remaining compounds showed in the 
virucidal assay the same behavior as in the antiviral test (data not shown). 
The major finding of the present study is the demonstration that many known 
antiretroviral Zn-finger active compounds with diverse chemical structures have 
inhibitory activity against arenaviruses. Although the majority of the most active 
substances were disulfide-based compounds, a more wide spectrum of related 
compounds must be tested to clearly establish direct structure-activity relationships. 
The mode of action of Zn-finger active compounds against HIV is destruction of Zn-
finger motifs in the nucleocapsid protein NCp7. At present, the mode of action against 
arenaviruses is unclear and further research is required to explain the different behavior 
of the compounds and elucidate if the compounds interact with Zn-finger domains in 
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arenavirus proteins or act through another mechanism. However, the ability of 
NSC20625 and other compounds to inactivate JUNV and TACV virions was 
coincidental with the virucidal activity against HIV shown by these agents, which 
entered the intact HIV particle and caused viral inactivation by cross-linking the NCp7 
protein after Zn ejection (Rice et al., 1997a; Tummino et al., 1997). It is noteworthy that 
the disulfide compounds most active in vitro against arenaviruses had also shown the 
highest ability to eject Zn from the NCp7 protein of HIV as reported by Rice et al. 
(1996). Studies are in progress to test the ability of these inhibitors to eject Zn from a 
recombinant arenavirus Z protein and, consequently, alter its interaction with other viral 
proteins in virions leading to loss of infectivity.  
Zn-finger proteins are essential to normal cellular function. However, it must be 
remarked  that the noncytotoxic effect of  these inhibitors was observed even for a more 
prolonged period of incubation, up to 6 days (data not shown). Furthermore, 
experimental evidence was presented that three antiviral agents that target retroviral 
nucleocapsid protein Zn-fingers, including the dithiane NSC624151, did not impact the 
functions of cellular Zn-finger proteins (Huang et al., 1998). Thus, the anti-arenavirus 
efficacy of compounds reported here without cellular toxicity in tissue culture is 
indicative of a true selective reactivity which enhances the future perspectives of this 
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Legend to the Figure 
 
Figure 1. Concentration-response curves for antiviral (A, B) and virucidal (C,D) 
activity of compounds against JUNV, strain IV4454, (A, C) and TACV (B, D). 
Antiviral activity was measured by virus yield inhibition assay at 48 h p.i. To determine 
virucidal activity virus samples were treated with the indicated compound 
concentrations for 1.5 h at 37°C and remaining infectivity was titrated. The data 
represent the average values from duplicate independent experiments. 
 
 
 
 
 
 
 
 
